The idea that 'young blood' might rejuvenate aging comes from animal studies showing that joining the bloodstreams of old and young mice (called heterochronic parabiosis) improves cognitive and physical function in the older animals. Researchers believe this happens because young blood contains beneficial factors that aren't present in old blood, and old blood contains harmful factors that accumulate with age. A human trial showed that simply removing patients' own plasma and replacing it with saline and albumin slowed cognitive decline in Alzheimer's patients—but that didn't test whether adding young donor plasma would work better.
This Norwegian pilot study went a step further: they directly replaced large volumes of plasma (16–26 liters) from 12 patients with mild cognitive impairment and Alzheimer's biomarkers with plasma from donors aged 18–24. They tested three different treatment schedules on different groups (3–5 patients each), spacing out the exchanges to give the young plasma time to circulate throughout the body and into the interstitial fluid (fluid surrounding cells). This is an ambitious approach to test the 'young blood' hypothesis in humans.
The key finding: all treatments were safe and feasible. No serious adverse events were reported. Patients tolerated the procedures, the logistics were manageable, and the team successfully demonstrated they could deliver and monitor this intervention. They also collected preliminary cognitive data and measured various blood biomarkers, though with only 12 patients and no control group, these results are more observational than conclusive.
However, this is explicitly a safety and feasibility study—not a test of efficacy. The authors cannot tell you whether young plasma actually slowed or halted cognitive decline because there was no comparison group. The sample is tiny (12 patients), there's no long-term follow-up data, and cognitive changes could be due to placebo effect, natural disease course, or regression to the mean. The study is also a preprint, not yet peer-reviewed, and cites zero prior publications (suggesting this is very early-stage work).
What this means: if these results hold up in peer review and a larger randomized controlled trial shows cognitive benefit, this could become an important treatment avenue for early Alzheimer's. But we're still in the 'does it work?' phase. The study demonstrates that the procedure *can* be done safely in humans, which is a necessary first step—but a long way from proof of benefit. The biological mechanism (whether young plasma actually reverses cognitive aging in humans) remains unknown.
For longevity research, this represents a rare human test of the heterochronic parabiosis concept, moving us beyond animal models. But it's preliminary, and skepticism is warranted until larger, controlled trials with blinded outcome assessment are completed.
0 Comments
Log in to join the discussion.